QED has been awarded a critical proof of concept study in the area of liver disease. QED will be responsible for the project management and clinical monitoring of this phase II trial. QED Director UK Operations, Susan Ollier, commented “This is a highly interesting study and QED has current experience of working on another phase II study being run in a number of key Hepatology centres. We are delighted to be able to build on these existing current links to the right institutions that could be involved in this latest trial”. QED’s involvement in this study is planned to last until August 2012.